Technology Innovation, People Centric
Adhering to the mission of providing trustworthy and universal access to state-of-the-art solutions of prolonging and reshaping all lives, Endovastec™ is committed to building a leading enterprise of emerging technologies in great vessel surgery and peripheral vascular medicine.
Products
Endovastec™ focuses on the research and development (R&D), manufacturing, sales and services of aortic, peripheral vascular and tumor intervention devices,and our main products are thoracic and abdominal aortic stent grafts, stent grafts in surgical operation, peripheral vascular stents, drug-coated balloon dilatation catheters, balloon dilatation catheters, vena cava filters and snare retrieval kits etc.
News
Endovastec™’s Minos™ Receives CE MDR Certification and Gains Market Approval in Egypt
The Minos™ Abdominal Aortic Stent Graft and Delivery System (Minos™), developed by Endovastec™, recently received CE MDR (Medical Device Regulation (EU) 2017/745) certification and market approval in Egypt - a milestone in its global market expansion.
15 May 2025
Endovastec™ Receives Market Approval for Talos™ in Brazil and Argentina
Endovastec™ announced that its Talos™ Thoracic Stent Graft System (Talos™) has recently received marketing approval in Brazil and Argentina, marking an important milestone in the company’s global strategy and its commitment to improving patient access to advanced aortic therapies.
25 Apr 2025
Endovastec™ Announces Annual Results for 2024: Global Expansion Accelerates as Innovation Drives Quality Development
During the Reporting Period, the Company achieved revenue of RMB 1.206 billion, with a net profit attributable to shareholders of listed companies of RMB 502 million and basic earnings per share of RMB 4.07.
28 Mar 2025